Shaping global life sciences strategy by mapping value, HTA, and payer policy trends

Situation

The client established a new, above-brand, cross-functional steering committee that would shape the company’s global policy and advocacy strategy. The committee needed a mechanism to track and analyze extensive information on trends in value, HTA, and payer policies across major markets in priority therapeutic areas such as oncology, specialty drugs, and vaccines. The committee also sought information on opportunities to engage with key multilateral organizations and global value influencers. In addition to monitoring these developments, the client aimed to translate this information into comprehensive, multi-level strategies in prioritized therapeutic areas across markets.

Solution

We created a three-stage quarterly workflow to provide in-depth business intelligence on the client’s markets and therapeutic areas of interest.

Success

The client’s global steering committee has used our quarterly analyses and recommendations to develop in-depth business intelligence on emerging trends in value, HTA, and payer policies in priority international markets and therapeutic areas, helping the organization to establish a strong, above-brand policy and access strategy worldwide. These quarterly reports serve as pre-read decks for steering committee meetings and the recommendations contained in the reports guide steering committee agendas.

Service

Policy

Get in touch to leverage our connected policy, access, value, and evidence solutions

Working across the product and service life cycle, from pre-clinical to post-launch, we partner with our clients to navigate the complex and rapidly changing healthcare ecosystem. Get in touch for a confidential conversation about how we can support you with your policy, access, value, and evidence strategies.